Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride

达格列净丙二醇一水化物/盐酸沙格列汀

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride
Drug Alias Namedapagliflozin propanediolSaxagliptin/dapagliflozinsaxagliptin/dapagliflozin propanediol monohydratedapagliflozin propanediol/saxagliptin hydrochlorideDapagliflozin Propanediol Monohydrate/Saxagliptin +[10] 
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsDipeptidyl peptidase IV inhibitors
TargetsSodium/glucose cotransporter 2Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2016/07/15
Country/TerritoryUnited StatesEU
CombinationsYes Dapagliflozin Propanediol MonohydrateSaxagliptin Hydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Ab
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD21
Related LinksKEGG